tbuckley/cabot-search huggingface dataset:
WASHINGTON NEWS
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Increased Use of Medicare Telehealth During the Pandemic
Authors: Melissa Suran
Journal: JAMA (2022)

Increased Use of Medicare Telehealth During the PandemicTelehealth visits for Medicare beneficiaries have increased significantly since the COVID-19 pandemic began, according to a report from the US Department of Health and Human Services (HHS).Researchers in HHS' Office of the Assistant Secretary for Planning and Evaluation reviewed 2019 and 2020 Medicare health care utilization trends.The authors found that overall Medicare Part B visits-when accounting for both in-person and telehealthdecreased from 1.1 billion in 2019 to approximately 989 million in 2020.However, 2020 telehealth visits increased to 52.7 million from approximately 840 000 in 2019.Ninetytwo percent of telehealth visits occurred in beneficiaries' homes, which generally wasn't permitted before the pandemic.To reduce COVID-19 exposure in health care environments, the US Centers for Medicare & Medicaid Services (CMS) authorized waivers in March 2020 that expanded telehealth services for Medicare beneficiaries.These waivers allowed for telehealth inhome visits, services in urban areas, and audio-only interaction for some services.HHS' report noted that in 2020, a greater proportion of beneficiaries in urban than rural areas used telehealth services.Whereas Massachusetts, Vermont, Rhode Island, New Hampshire, and Connecticut were among states with the highest use of telehealth services in 2020, those with the lowest use included Tennessee, Nebraska, Kansas, North Dakota, and Wyoming.White Medicarebeneficiariesweremorelikelytouse telehealth services than Black beneficiaries.Among clinicians, behavioral health specialists had the highest increase in telehealth visits.In 2019, only 1% of visits to behavioral health specialists were telehealth; in 2020, the percentage jumped to 38.1%.By the end of 2020, telehealth visits to behavioral specialists were as common as inperson visits."This report provides valuable insights into telehealth usage during the pandemic," CMS Administrator Chiquita Brooks-LaSure, MPP, said in a statement."CMS will use these insights-along with input from people with Medicare and providers across the country-toinformfurtherMedicaretelehealthpolicies."Coverage of COVID-19 Vaccine Counseling for Children and Youths
External validation and head-to-head comparison of all the prognostic models recommended by the European Association of Urology guidelines to predict oncologic outcomes in patients with renal cell carcinoma
Authors: C. Giancristofaro, G. Rosiello, G. Fallara, A. Martini, G. Colandrea, G. Basile, D. Cignoli, L. Nocera, G. Baiamonte, A. Nini, W. Cazzaniga, D. Canibus, I. Rowe, G. Musso, F. Cei, M. Romani, A. Briganti, R. Bertini, F. Montorsi, A. Salonia, A. Larcher, U. Capitanio
Journal: European Urology (2021)
Antibacterial biomaterials for skin wound dressing
Authors: Yuqing Liang, Yongping Liang, Hualei Zhang, Baolin Guo
Journal: Asian Journal of Pharmaceutical Sciences (2022)

Bacterial infection and the ever-increasing bacterial resistance have imposed severe threat to human health. And bacterial contamination could significantly menace the wound healing process. Considering the sophisticated wound healing process, novel strategies for skin tissue engineering are focused on the integration of bioactive ingredients, antibacterial agents included, into biomaterials with different morphologies to improve cell behaviors and promote wound healing. However, a comprehensive review on anti-bacterial wound dressing to enhance wound healing has not been reported. In this review, various antibacterial biomaterials as wound dressings will be discussed. Different kinds of antibacterial agents, including antibiotics, nanoparticles (metal and metallic oxides, light-induced antibacterial agents), cationic organic agents, and others, and their recent advances are summarized. Biomaterial selection and fabrication of biomaterials with different structures and forms, including films, hydrogel, electrospun nanofibers, sponge, foam and three-dimension (3D) printed scaffold for skin regeneration, are elaborated discussed. Current challenges and the future perspectives are presented in this multidisciplinary field. We envision that this review will provide a general insight to the elegant design and further refinement of wound dressing.
Adolescents’ psychosocial well-being one year after the outbreak of the COVID-19 pandemic in Norway
Authors: Tilmann von Soest, Michal Kozák, Rubén Rodríguez-Cano, Sam Fluit, Laura Cortés-García, Vidar S. Ulset, E. F. Haghish, Anders Bakken
Journal: Nature Human Behaviour (2022)
Xray and US free calix puncture before PCNL (XUF PCNL). Comparison with standard Xray/US guided puncture
Authors: M. Maltagliati, L. Berti, C. Buizza, U. Besana, L. Rivolta, C. Gastaldi, A. Calori, G. Malvestiti, M.C. Sighinolfi, S. Micali, B. Rocco, G. Bozzini
Journal: European Urology (2021)
Prevalence, Intensity, and Clinical Impact of Dyspnea in Critically Ill Patients Receiving Invasive Ventilation
Authors: Alexandre Demoule, David Hajage, Jonathan Messika, Samir Jaber, Hassimiou Diallo, Maxime Coutrot, Achille Kouatchet, Elie Azoulay, Muriel Fartoukh, Sami Hraiech, Pascal Beuret, Michael Darmon, Maxens Decavèle, Jean-Damien Ricard, Gerald Chanques, Alain Mercat, Matthieu Schmidt, Thomas Similowski, Morgane Faure, Suela Demiri, Marie-Amelie Ordan, Maxime Mallet, Guillaume Berquier, Béatrice La Combe, Malo Emery, Abirami Thiagarajah, Fouad Belafia, Mathieu Capdevila, Yassir Aarab, Alain Combes, Guillaume Hekimian, Loic Le Gunnec, Cherifa Gouanne, Clementine Taconet, Laurent Papazian, Jean-Marie Forel, Christophe Guervilly, Mélanie Adda, Xavier Fabre, Jean-Charles Chakarian, Bénédicte Philippon-Jouve, Florian Michelin
Journal: American Journal of Respiratory and Critical Care Medicine (2022)

Rationale: Dyspnea is a traumatic experience. Only limited information is available on dyspnea in intubated critically ill patients. Objectives: Our objectives were 1) to quantify the prevalence and severity of dyspnea; and 2) to evaluate the impact of dyspnea on ICU length of stay and post-traumatic stress disorder (PTSD) 90 days after ICU discharge. Methods: This was a prospective cohort study in 10 ICUs in France. In patients intubated for more than 24 hours, dyspnea was quantified with a visual analog scale (from 0 to 10) as soon as they were able to communicate, the following day, and before spontaneous breathing trials. PTSD was defined by an Impact of Event Scale-Revised score of at least 22. Measurements and Main Results: Among the 612 patients assessed, 34% reported dyspnea, with a median dyspnea rating of 5 (interquartile range, 4-7). ICU length of stay was not significantly different between patients with versus without dyspnea (6 [3-12] and 6 [3-13] days, respectively; P = 0.781). Mortality was not different between groups. Of the 153 patients interviewed on Day 90, a higher proportion of individuals with probable PTSD was observed among patients who were dyspneic on enrollment (29% vs. 13%; P = 0.017). The density of dyspnea (number of dyspneic episodes divided by time from enrollment to extubation) was independently associated with PTSD (odds ratio, 1.07; 95% confidence interval, 1.01-1.13; P = 0.031). Conclusions: Dyspnea was frequent and intense in intubated critically ill patients. ICU length of stay was not significantly different among patients reporting dyspnea, but PTSD was more frequent at Day 90. Clinical trial registered with www.clinicaltrials.gov (NCT02336464).
Immunoglobulin E response in health and disease beyond allergic disorders
Authors: Luc Colas, Antoine Magnan, Sophie Brouard
Journal: Allergy (2022)

Immunoglobulin E is the latest discovered of immunoglobulin family and has been long associated with anaphylaxis and worm expulsion. Immunoglobulin E, along with mast cells, basophils, and eosinophils, is also a hallmark of type 2 immunity which is dysregulated in numerous diseases such as asthma, rhinitis, atopic dermatitis, and eosinophilic esophagitis in addition to anaphylaxis as aforementioned. However, recent advances have shed light on IgE regulation and memory explaining the low level of free IgE, the scarcity of IgE plasma cells that are mainly short live and the absence of IgE memory B cells in homeostatic conditions. Furthermore, IgE was implicated in inflammatory conditions beyond allergic disorders where IgE-mediated facilitated antigen presentation can enhance cellular and humoral response against autoantigens in systemic lupus or chronic urticaria leading to more severe disease and even against neoantigen facilitating tumor cell lysis. At last, IgE was unexpectedly associated with allograft rejection or atheromatous cardiovascular diseases where precise mechanisms remain to be deciphered. The purpose of this review is to summarize these recent advances in IgE regulation, biology, and physiopathology beyond allergic diseases opening whole new fields of IgE biology to explore.
Final validation of a Patient Reported Outcome Measure (PROM) for penile curvature surgery
Authors: M.U.V. Natarajan, D. Akiboye, M. Skrodzka, J. Harrison, S. Yan, E. Anastasiadis, P. Patel, B.E. Ayres, N.A. Watkin
Journal: European Urology (2021)
Artificial intelligence for diagnosis and Gleason grading of prostate cancer: the PANDA challenge
Authors: Wouter Bulten, Kimmo Kartasalo, Po-Hsuan Cameron Chen, Peter Ström, Hans Pinckaers, Kunal Nagpal, Yuannan Cai, David F. Steiner, Hester van Boven, Robert Vink, Christina Hulsbergen-van de Kaa, Jeroen van der Laak, Mahul B. Amin, Andrew J. Evans, Theodorus van der Kwast, Robert Allan, Peter A. Humphrey, Henrik Grönberg, Hemamali Samaratunga, Brett Delahunt, Toyonori Tsuzuki, Tomi Häkkinen, Lars Egevad, Maggie Demkin, Sohier Dane, Fraser Tan, Masi Valkonen, Greg S. Corrado, Lily Peng, Craig H. Mermel, Pekka Ruusuvuori, Geert Litjens, Martin Eklund, Américo Brilhante, Aslı Çakır, Xavier Farré, Katerina Geronatsiou, Vincent Molinié, Guilherme Pereira, Paromita Roy, Günter Saile, Paulo G. O. Salles, Ewout Schaafsma, Joëlle Tschui, Jorge Billoch-Lima, Emíio M. Pereira, Ming Zhou, Shujun He, Sejun Song, Qing Sun, Hiroshi Yoshihara, Taiki Yamaguchi, Kosaku Ono, Tao Shen, Jianyi Ji, Arnaud Roussel, Kairong Zhou, Tianrui Chai, Nina Weng, Dmitry Grechka, Maxim V. Shugaev, Raphael Kiminya, Vassili Kovalev, Dmitry Voynov, Valery Malyshev, Elizabeth Lapo, Manuel Campos, Noriaki Ota, Shinsuke Yamaoka, Yusuke Fujimoto, Kentaro Yoshioka, Joni Juvonen, Mikko Tukiainen, Antti Karlsson, Rui Guo, Chia-Lun Hsieh, Igor Zubarev, Habib S. T. Bukhar, Wenyuan Li, Jiayun Li, William Speier, Corey Arnold, Kyungdoc Kim, Byeonguk Bae, Yeong Won Kim, Hong-Seok Lee, Jeonghyuk Park
Journal: Nature Medicine (2022)

Abstract Artificial intelligence (AI) has shown promise for diagnosing prostate cancer in biopsies. However, results have been limited to individual studies, lacking validation in multinational settings. Competitions have been shown to be accelerators for medical imaging innovations, but their impact is hindered by lack of reproducibility and independent validation. With this in mind, we organized the PANDA challenge—the largest histopathology competition to date, joined by 1,290 developers—to catalyze development of reproducible AI algorithms for Gleason grading using 10,616 digitized prostate biopsies. We validated that a diverse set of submitted algorithms reached pathologist-level performance on independent cross-continental cohorts, fully blinded to the algorithm developers. On United States and European external validation sets, the algorithms achieved agreements of 0.862 (quadratically weighted κ, 95% confidence interval (CI), 0.840–0.884) and 0.868 (95% CI, 0.835–0.900) with expert uropathologists. Successful generalization across different patient populations, laboratories and reference standards, achieved by a variety of algorithmic approaches, warrants evaluating AI-based Gleason grading in prospective clinical trials.
Psoriasis and Cardiovascular Disease—An Ounce of Prevention Is Worth a Pound of Cure
Authors: Michael S. Garshick, Jeffrey S. Berger
Journal: JAMA Dermatology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity
Authors: Shinya Abe, Hiroshi Nagata, Erika J Crosby, Yoshiyuki Inoue, Kensuke Kaneko, Cong-Xiao Liu, Xiao Yang, Tao Wang, Chaitanya R Acharya, Pankaj Agarwal, Joshua Snyder, William Gwin, Michael A Morse, Pei Zhong, Herbert Kim Lyerly, Takuya Osada
Journal: Journal for ImmunoTherapy of Cancer (2022)

Despite multimodal adjuvant management with radiotherapy, chemotherapy and hormonal therapies, most surgically resected primary breast cancers relapse or metastasize. A potential solution to late and distant recurrence is to augment systemic antitumor immunity, in part by appropriately presenting tumor antigens, but also by modulating the immunosuppressive tumor microenvironment (TME). We previously validated this concept in models of murine carcinoma treated with a novel predominately microcavitating version of high-intensity focused ultrasound (HIFU), mechanical high-intensity focused ultrasound (M-HIFU). Here we elucidated the mechanisms of enhanced antitumor immunity by M-HIFU over conventional thermal high-intensity focused ultrasound (T-HIFU) and investigated the potential of the combinatorial strategy with an immune checkpoint inhibitor, anti-PD-L1 antibody.The antitumor efficacy of treatments was investigated in syngeneic murine breast cancer models using triple-negative (E0771) or human ErbB-2 (HER2) expressing (MM3MG-HER2) tumors in C57BL/6 or BALB/c mice, respectively. Induction of systemic antitumor immunity by the treatments was tested using bilateral tumor implantation models. Flow cytometry, immunohistochemistry, and single-cell RNA sequencing were performed to elucidate detailed effects of HIFU treatments or combination treatment on TME, including the activation status of CD8 T cells and polarization of tumor-associated macrophages (TAMs).More potent systemic antitumor immunity and tumor growth suppression were induced by M-HIFU compared with T-HIFU. Molecular characterization of the TME after M-HIFU by single-cell RNA sequencing demonstrated repolarization of TAM to the immunostimulatory M1 subtype compared with TME post-T-HIFU. Concurrent anti-PD-L1 antibody administration or depletion of CD4+ T cells containing a population of regulatory T cells markedly increased T cell-mediated antitumor immunity and tumor growth suppression at distant, untreated tumor sites in M-HIFU treated mice compared with M-HIFU monotherapy. CD8 T and natural killer cells played major roles as effector cells in the combination treatment.Physical disruption of the TME by M-HIFU repolarizes TAM, enhances T-cell infiltration, and, when combined with anti-PD-L1 antibody, mediates superior systemic antitumor immune responses and distant tumor growth suppression. These findings suggest M-HIFU combined with anti-PD-L1 may be useful in reducing late recurrence or metastasis when applied to primary tumors.
Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial
Authors: Deepali Kumar, Michael G Ison, Jean-Paul Mira, Tobias Welte, Jick Hwan Ha, David S Hui, Nanshan Zhong, Takefumi Saito, Laurie Katugampola, Neil Collinson, Sarah Williams, Steffen Wildum, Andrew Ackrill, Barry Clinch, Nelson Lee
Journal: The Lancet Infectious Diseases (2022)
Controversies Around the Measurement of Blood Ketones to Diagnose and Manage Diabetic Ketoacidosis
Authors: Eric S. Kilpatrick, Alexandra E. Butler, Linda Ostlundh, Stephen L. Atkin, David B. Sacks
Journal: Diabetes Care (2022)

The measurement of blood ketones in preference to urine ketones has become a well-established tool in the diagnosis and management of diabetic ketoacidosis (DKA). However, there remains considerable disparity between diabetes guidelines regarding if, how, and when this test should be used. While recent guidelines now mainly emphasize blood measurement, several issues nonetheless remain. Many laboratories still measure blood ketones using a semiquantitative test that does not measure the predominant ketone, β-hydroxybutyrate (BOHB), which may hinder patient management. Even when BOHB is measured, the evidence for cutoffs used in DKA diagnosis or exclusion is limited, while its use in gauging severity, treatment progress, and resolution is not fully clear. Lastly, although employing point-of-care meters instead of a laboratory for BOHB measurement brings undoubted benefits, this approach has its own challenges. This article provides a perspective on these topics to complement current recommendations and to suggest how future research may improve its use in the DKA context.
The learning curve of mpMRI targeted biopsy for the detection of clinically significant prostate cancer is related to the characteristics of the index lesion
Authors: A. Stabile, E. Mazzone, F. Barletta, C.A. Bravi, G. Rosiello, V. Cucchiara, G. Sorce, F. Pellegrino, E. Zaffuto, G. Brembilla, A. Esposito, G. Gandaglia, N. Fossati, A. Gallina, F. Dehò, F. De Cobelli, F. Montorsi, A. Briganti
Journal: European Urology (2021)
Cumulative Advanced Breast Cancer Risk Prediction Model Developed in a Screening Mammography Population
Authors: Karla Kerlikowske, Shuai Chen, Marzieh K Golmakani, Brian L Sprague, Jeffrey A Tice, Anna N A Tosteson, Garth H Rauscher, Louise M Henderson, Diana S M Buist, Janie M Lee, Charlotte C Gard, Diana L Miglioretti
Journal: JNCI Journal of the National Cancer Institute (2022)

Abstract Background Estimating advanced breast cancer risk in women undergoing annual or biennial mammography could identify women who may benefit from less or more intensive screening. We developed an actionable model to predict cumulative 6-year advanced cancer (prognostic pathologic stage II or higher) risk according to screening interval. Methods We included 931 186 women aged 40-74 years in the Breast Cancer Surveillance Consortium undergoing 2 542 382 annual (prior mammogram within 11-18 months) or 752 049 biennial (prior within 19-30 months) screening mammograms. The prediction model includes age, race and ethnicity, body mass index, breast density, family history of breast cancer, and prior breast biopsy subdivided by menopausal status and screening interval. We used fivefold cross-validation to internally validate model performance. We defined higher than 95th percentile as high risk (&amp;gt;0.658%), higher than 75th percentile to 95th or less percentile as intermediate risk (0.380%-0.658%), and 75th or less percentile as low to average risk (&amp;lt;0.380%). Results Obesity, high breast density, and proliferative disease with atypia were strongly associated with advanced cancer. The model is well calibrated and has an area under the receiver operating characteristics curve of 0.682 (95% confidence interval = 0.670 to 0.694). Based on women’s predicted advanced cancer risk under annual and biennial screening, 69.1% had low or average risk regardless of screening interval, 12.4% intermediate risk with biennial screening and average risk with annual screening, and 17.4% intermediate or high risk regardless of screening interval. Conclusion Most women have low or average advanced cancer risk and can undergo biennial screening. Intermediate-risk women may consider annual screening, and high-risk women may consider supplemental imaging in addition to annual screening.
Multicentric experience in Retzius-sparing robot assisted radical prostatectomy performed by expert surgeons for high risk prostate cancer
Authors: A. Galfano, S. Tappero, P. Dell’Oglio, C. Eden, K. Fransis, H. Guo, K. Kowalczyk, R. Madi, K.H. Rha, S. Secco, A.M. Bocciardi
Journal: European Urology (2021)
Examining the impact of airborne pollution on eczema
Journal: British Journal of Dermatology (2020)

Atopic dermatitis (also known as AD or eczema) is an extremely common inflammatory skin condition.The prevalence (how common it is) of eczema has increased over recent decades.This has occurred alongside an increase in industrialisation and urban living, in which we are exposed to more environmental pollutants during the course of our daily activities.The aim of this review, from the U.S.A., was to highlight the impact of pollution on the skin's functioning, examine the evidence linking pollution with AD, explain how this process works, and how we might reduce or prevent pollution-based damage to the skin.Pollutants were found to cause oxidative stress in the skin, which damages the skin barrier.This barrier is provided by the outmost layer of skin, and prevents potentially harmful things, such as bacteria, allergens and irritants, from entering the body, as well as preventing excessive water loss.The skin barrier is often not as effective in people with eczema, and both long-and short-term pollutant exposure have been linked to worsening of symptoms and increased eczema rates in population studies.Airborne pollutants were found to cause this disruption through several mechanisms in the skin.Patients should be encouraged to wash daily (preferably at the end of the day following exposure to pollution), with subsequent moisturiser (emollient) application to help skin barrier repair.Further research is needed to fully understand how pollutants cause skin barrier dysfunction.This is a complex area as the skin is exposed to several substances per day, and environmental factors including temperature, humidity and ultraviolet light are likely to interact with environmental pollutants, and impact how they affect the skin.